Objectives: Stage III melanoma is associated with an increased risk of recurrence and death. Complete surgical resection remains the best chance for cure. Unfortunately, no adjuvant therapy has demonstrated a consistent improvement in melanoma-specific survival (MSS). We hypothesize that adjuvant granulocyte-macrophage colony-stimulating factor (GM-CSF) may improve clinical outcomes.
L ymphatic metastases are the single most important prognostic factor in patients with melanoma. The 5-year overall survival rate for patients with stage III disease is approximately 50%. 1 Survival decreases with increasing nodal tumor burden, measured as an increasing number of lymph nodes involved and increasing size of metastasis. 1 When possible, surgical resection remains the most promising opportunity for long-term survival. Despite having (clinical or measurable) disease confined to the primary site and regional basin, this population is at very high risk of distant relapse and death secondary to clinically occult micrometastatic disease present at the time of diagnosis, which progresses during follow-up. The ability to prevent further progression and control these unrecognized disseminated tumor cells is the goal of adjuvant therapy, ultimately culminating in improved patient survival.
Melanoma impairs the antitumor immune response within nearby lymph nodes. Tumor draining lymph nodes contain fewer and less mature or activated dendritic cells suggesting poor antigen presentation capabilities. Furthermore, there is a reduction in T-cell number and function, leading to melanoma progression and dissemination. 2 Restoration of the locoregional and systemic immunity to a level that controls the progression of melanoma may lead to prolonged survival. Interferon-a (IFN-a) is currently the only FDA-approved adjuvant therapy for stage III melanoma and offers a modest improvement in disease-free survival (DFS) and minimal, if any, improvement in overall survival. IFN-a is poorly tolerated, and the optimal dose, treatment duration, and subset of patients most likely to benefit from therapy have not been elucidated. 3 Granulocyte-macrophage colony-stimulating factor (GM-CSF) activates the innate immune system by stimulating the cytotoxicity of peripheral blood monocytes 4, 5 and is the principle mediator of dendritic cell proliferation, maturation, and migration. [6] [7] [8] GM-CSF also stimulates tumorinfiltrating macrophages to produce more angiostatin that suppresses angiogenesis, a critical component in the metastatic cascade. 9 This restoration of the innate immune system may be beneficial for patients rendered surgically no evidence of disease and at high risk for recurrence and death.
Despite the limited data on GM-CSF and lack of FDA approval, our institution has been utilizing adjuvant GM-CSF for the past decade because of the poor tolerability, poor response, and relative lack of survival benefit of IFN-a. This study reports on the largest clinical experience with adjuvant GM-CSF in patients with melanoma. The aim of this study is to compare outcomes of 2 different postoperative management regimens in patients with stage III melanoma, specifically observation or adjuvant GM-CSF in a retrospective cohort study.
MATERIALS AND METHODS
After Institutional Review Board approval, we performed a retrospective cohort study of all adult patients with stage III melanoma treated at the Mayo Clinic (Rochester) from January 1, 2001 to December 30, 2010. Clinical and demographic data were collected and managed using REDCap (Research Electronic Data Capture) electronic data capture tools hosted at Mayo Clinic. 10 Joint Commission on Cancer (AJCC) 7th edition. Adjuvant treatment after complete surgical resection and staging was divided into expectant observation and GM-CSF according to the Spitler et al regimen 11 (GM-CSF administered at 250 mcg/ d subcutaneous for 14 d of a 28-d cycle) given for 1 to 3 years or until recurrence. 11 Patients treated with IFN-a were excluded from analysis. Patients treated in clinical trials with vaccine therapy (n = 43) were included in the observation cohort as the group was too small for separate analysis and no vaccine therapy has been demonstrated to be superior to observation. Patients who received at least 1 dose of GM-CSF within 90 days of their definitive surgical procedure were included using an intention-to-treat analysis. Patients with initial stage III disease and those with earlier-stage melanoma who subsequently developed a nodal recurrence were included. However, patients who had recurrent disease were only included if they had the recurrence completely excised and were observed or began adjuvant GM-CSF therapy within 90 days of the surgery for stage III disease. The date of complete resection of all disease was utilized as the start date for all patients, and patients who were lost to follow-up or died secondary to unrelated causes were censored at time of last follow-up.
Statistical Analysis
Descriptive statistics are reported as median and interquartile range or number and frequency. Clinical and pathologic characteristics for the 2 cohorts were compared using the Wilcoxon rank-sum test or Student t test as appropriate. Patient survival and recurrence survivals at 1, 3, 5, and 10 years were estimated using the Kaplan-Meier method. Univariate and multivariate associations between observation and adjuvant GM-CSF and locoregional or distant recurrence and melanoma-specific survival (MSS) were assessed using Cox proportional hazards regression. The magnitude of associations is reported as hazard ratios (HRs) and 95% confidence interval (CI). The following variables were included in univariate analysis for each outcome; treatment, age, sex, Breslow depth, ulceration, location, recurrence, or primary, AJCC stage (IIIA, IIIB, and IIIC), Eastern Cooperative Oncology Group status (0 vs. Z1). The multivariate model was chosen using a backward selection method, although forward and stepwise selection procedures also happen to have yielded the same final models. All statistical tests were 2-sided, with a P-values of r0.05 were considered statistically significant. All statistical analysis was performed using SAS software.
RESULTS

Patient Characteristics
Over the 10-year study period, 317 patients with stage III disease were followed for a median of 34 months. Survivors were followed for a median of 44 months. There were 165 (52%) patients observed expectantly with history and physical examination every 3 to 6 months, imaging as per physician discretion, and at minimum annual dermatological examinations including the skin and lymph node basins. There were 152 (48%) patients treated with adjuvant GM-CSF in addition to routine surveillance. The clinical and pathologic characteristics of the 2 cohorts are illustrated in Table 1 . Briefly, the group of patients treated with GM-CSF tended to be younger (P < 0.0001), had more advanced stage disease (P = 0.002), and were more likely to have had a recurrence before initiation of adjuvant therapy than the observation group (P < 0.0001).
DFS
The median DFS was 36 months with a 1, 3, and 5-year DFS of 72%, 50%, and 40%, respectively. Nearly half (49%) of the recurrences occurred within the first year of follow-up. The median DFS for patients who were observed expectantly was 47 months compared with 29 months for those treated with GM-CSF ( Fig. 1A) . There was no significant difference in DFS for the different treatment groups as a whole, as well as within each stage separately (IIIA, IIIB, and IIIC). Adjuvant GM-CSF seemed to prolong DFS within the 89 patients with stage IIIC melanoma; however, this did not reach significance (P = 0.14) (Fig. 1B) . In univariate analysis, sex, age, Breslow depth, AJCC stage (IIIA, IIIB and IIIC), recurrence, and adjuvant regional radiation were significantly associated with DFS; however, type of adjuvant systemic treatment was not associated with DFS (P = 0.38). To correct for significant clinical and demographic prognostic factors, a Cox proportional hazards model that included the variables from the univariate analysis that remained after backward selections was applied. This analysis confirmed that male sex (males: HR 2.38; 95% CI, 1.56-3.64; P < 0.0001), older age (per year: HR 1.01; 95% CI, 1.00-1.02; P = 0.047), increased Breslow depth (per mm: HR 1.06; 95% CI, 1.01-1.13; P = 0.03), and advanced AJCC stage (IIIB: HR 2.2; 95% CI, 1.43-3.4; P < 0.001 and IIIC: HR 3.96; 95% CI, 2.48-6.33; P < 0.0001) remained independently associated with a worse DFS ( Table 2) . Treatment type was not associated with DFS in multivariate analysis of the entire cohort.
MSS
The median MSS for the entire cohort was 103 months with a 3, 5, and 10-year MSS of 73%, 62%, and 43%, respectively. The median MSS for patients who were observed expectantly was 99 months compared with 102 months for those treated with GM-CSF. The 3, 5, and 10-year MSS for patients treated with adjuvant GM-CSF was 77%, 67%, and 49%, respectively, and 68%, 57%, and 39% for those who were observed, respectively. This improvement in MSS with adjuvant GM-CSF over observation approached but did not reach significance (P = 0.08) ( Fig. 2A) . In univariate analysis, sex, age, Breslow depth, ulceration, Eastern Cooperative Oncology Group status, and AJCC stage (IIIA, IIIB, and IIIC) were significant predictors of MSS. In multivariate analysis, sex (males: HR 2.45; 95% CI, 1.35-4.43; P = 0.003), older age (per year: HR 1.03; 95% CI, 1.01-1.04; P = 0.002), increasing Breslow depth (per mm: odds ratio 1.1; 95% CI, 1.02-1.18; P = 0.012) and stage IIIC (odds ratio 3.29; 95% CI, 1.87-5.77; P < 0.001) remained independently associated with a worse MSS ( Table 2 ). Adjuvant GM-CSF was not independently associated with improved MSS in multivariate analysis (P = 0.19) compared with observation. However, within the subgroup of stage IIIC patients, GM-CSF relative to observation was significantly associated with a 52% lower risk of melanoma-specific mortality (HR 0.48; 95% CI, 0.27-0.87; P = 0.02) (Fig. 2B ). This improvement in MSS was not seen in patients with less advanced stage III disease (IIIA and IIIB).
DISCUSSION
We report the largest experience of adjuvant GM-CSF in patients with melanoma. In our study of patients with surgically resected stage III melanoma, we observed that the stage IIIC population receiving adjuvant GM-CSF experienced a >50% relative reduction in melanoma-specific deaths compared with the observation group. This benefit was only seen in those with advanced stage IIIC disease and not the stage IIIA or IIIB cohorts. Our results are similar to preliminary studies done by Spitler et al 11 who first reported prolonged overall survival and DFS in 48 patients with stage III or IV melanoma treated with adjuvant GM-CSF compared with matched historical controls. It is worth highlighting that the stage III inclusion criteria for Spitler and colleagues phase II clinical trial included >4 positive nodes or a nodal mass >3 cm in diameter suggesting that most of the patients were stage IIIC; the same cohort we found derived the most benefit from adjuvant GM-CSF. A subsequent single-arm clinical trial by Spitler et al 12 of 98 patients with stage II, III, and IV melanoma reported 5-year MSS for stage III and IV patients of 67% and 40%, respectively, which compare favorably with historical controls. The largest group in their study consisted of patients with stage IIIC disease and over half of the study population was stage IIIB or IIIC, with only 5% stage II.
Similarly, multiple phase II clinical trials including patients with stage II, III, and IV melanoma treated with sequential GM-CSF and interleukin-2 with or without autologous vaccine reported benefit for high-risk patients with surgically resected melanoma, [13] [14] [15] although it is not clear how much each individual component provided benefit. Together, these results suggest that adjuvant GM-CSF is effective in prolonging MSS in a subset of patients with highrisk melanoma.
In our study, we did not see an improvement in DFS; however, the Kaplan-Meier graph in Figure 1B suggests that there could potentially be a delay in recurrences in the stage IIIC patients treated with adjuvant GM-CSF. The delay in recurrence was not significant, although this may be due to the small sample size. It is reasonable to postulate that the activated macrophages and dendritic cells from GM-CSF treatment alone may not be able to completely eliminate microscopic residual disease, but in a subset of patients suppresses the growth of these malignant cells while therapy is ongoing. Interestingly, Spitler et al 11 also observed a greater effect of adjuvant therapy with GM-CSF on overall survival than on DFS, as well as an increase in disease recurrences when patients stopped treatment after 1 year. She subsequently has increased the duration of treatment with GM-CSF to 3 years and has reported a longer median DFS and a longer median survival that has not yet been reached after 5.3 years of followup. 12 Since her publication, we have gone to a longer 3-year course of GM-CSF. In our patients who develop local-regional or oligometasatic distant recurrence and undergo ablation or resection, we also resume GM-CSF once rendered no evidence of disease. Our clinical outcome data, although intriguing and confirmatory of other smaller series, remain hypothesis generating in terms of mechanistic explanations of the findings.
Our study confirms the heterogenous nature of stage III melanoma as the prognosis varied from 80% 5-year MSS for stage IIIA melanoma to 22% 5-year MSS for stage IIIC melanoma. As such, patients with stage IIIA melanoma seem to do well regardless of treatment type and therefore may be best served with close surveillance. The low number of events in this cohort likely diluted the beneficial effects of our analysis when combining all the stage III patients into 1 group. In contrast, patients with stage IIIC melanoma are at high risk of subsequent relapse and death and the high number of events allow for the benefit from adjuvant GM-CSF to be demonstrated despite the study size. The prognosis for stage IIIB patients is more intermediate, and therefore, the benefit from adjuvant GM-CSF may be smaller, requiring a much larger sample size to demonstrate, if indeed, a difference does exist. Better prognostic markers are needed to clarify the stage IIIB patients at highest risk of relapse who may benefit from adjuvant therapy. This retrospective cohort study is limited by its very design, in that there is inherent selection bias in the clinical decision to observe or provide adjuvant therapy, and if adjuvant therapy is to be administered, which type. As illustrated in Table 1 , patients with more advanced stage and recurrent disease are more likely to receive intervention, in this case adjuvant GM-CSF. Expectant observation was most frequently favored for patients at lower risk for recurrence and this group was also on average older. These differences are likely to underestimate the benefit of adjuvant GM-CSF, and we have attempted to control for this by multivariate analysis using a Cox proportional hazards model. Another weakness of this study is the small sample size that limits our ability to derive conclusions from subgroup analysis. We also chose to include vaccine-treated patients in the observation arm. Although there are some data to suggest that patients may have done worse on vaccine arms. 16 We found no significant difference in DFS or MSS between the observed cohort and the cohort receiving vaccine (data not shown) and therefore did not exclude these patients. This study represents the largest reported experience with adjuvant GM-CSF and provides additional support for its use in high-risk patients.
In conclusion, despite its inherent limitations, the current study has expanded the preliminary evidence on GM-CSF as an adjuvant therapy for patients with melanoma who are at high risk for recurrence and death. Our study is consistent with previous studies by Spitler et al, 11, 12 demonstrating an improvement in MSS for advanced stage III patients and lends further support for the use of adjuvant GM-CSF in the highest risk cohort. Additional evidence regarding the efficacy of adjuvant GM-CSF therapy will await the results of the E4697, a phase III clinical trial that randomizes stage IIIB, IIIC, and IV melanoma to GM-CSF or placebo for 1 year. This trial has completed accrual and has been presented in abstract form. 17 
